Login to Your Account



Pharma: Other News To Note


Thursday, September 5, 2013
Tris Pharma Inc., of Monmouth Junction, N.J., and FSC Laboratories Inc., of Charlotte, N.C., signed a license agreement for commercialization of Karbinal ER (carbinoxamine maleate) extended-release oral suspension, a sustained-release histamine receptor blocking agent for allergic rhinitis in children 2 and older.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription